Subtype
Pancreatic Ductal Adenocarcinoma
CI-CAN-00008194PDA · PDACExplore in graph →
208 active trials11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00008194PDA · PDACExplore in graph →
Clinical trials
414 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05201729 | Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer | unknown | — | 30 | Ruijin HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03331640 |
| A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) |
| terminated |
| Phase 2 |
| 67 |
| AIO-Studien-gGmbHOTHER |
| 1 |
| Jan 11, 2022 |
| clinicaltrials |
| NCT05168254 | Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer | unknown | — | 50 | Ruijin HospitalOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02787187 | Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended? | completed | N/A | 230 | Ruijin HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04310111 | EUS-RFA for Unresectable Pancreatic Cancer | completed | N/A | 8 | First People's Hospital of HangzhouOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04954378 | Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer | completed | — | 300 | Peking University Third HospitalOTHER | 0 | Jul 8, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 | Jul 2, 2021 | clinicaltrials |
| NCT03865875 | Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program | unknown | N/A | 40 | Massachusetts General HospitalOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04211948 | Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer | unknown | N/A | 300 | Ruijin HospitalOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04802993 | Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate | completed | — | 5,123 | Linkoeping UniversityOTHER_GOV | 0 | Mar 17, 2021 | clinicaltrials |
| NCT04794140 | A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC | unknown | N/A | 60 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT03770117 | Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease(SIPUP) | completed | — | 113 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03138213 | Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy | unknown | N/A | 656 | Tongji HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03794128 | A Study of Personalized Neoantigen Cancer Vaccines | completed | — | 93 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02790944 | Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer | completed | — | 300 | Ambry GeneticsINDUSTRY | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | Early Phase 1 | 2 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT04189393 | Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery(MA-PPING) | unknown | — | 60 | Radboud University Medical CenterOTHER | 0 | Dec 6, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT04164992 | Endoscopic Ultrasound Radiofrequency Ablation (EUS-RFA) of Not-resectable Pancreatic Cancer | unknown | N/A | 15 | Campus Bio-Medico UniversityOTHER | 0 | Nov 18, 2019 | clinicaltrials |
| NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | unknown | Phase 2 | 60 | Wakayama Medical UniversityOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT03951324 | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study(VLE-IOV) | unknown | — | 40 | Innovative Digestive Health Education and Research IncOTHER | 1 | Aug 12, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03973736 | Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational Study(RevRadPAC) | completed | — | 316 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 30, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03634332 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | unknown | Phase 2 | 35 | Pancreatic Cancer Research TeamOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study | terminated | Phase 1 | 1 | University of ChicagoOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02440958 | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | completed | Phase 2 | 50 | Yonsei UniversityOTHER | 0 | Feb 18, 2019 | clinicaltrials |
| NCT02570529 | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | withdrawn | Phase 4 | 0 | Yonsei UniversityOTHER | 0 | Jan 29, 2019 | clinicaltrials |
| NCT03687853 | Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery | unknown | N/A | 80 | Peking University Third HospitalOTHER | 1 | Sep 27, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT02657330 | Study of SBP-101 in Pancreatic Cancer | completed | Phase 1 | 29 | Panbela Therapeutics, Inc.INDUSTRY | 2 | Apr 20, 2018 | clinicaltrials |
| NCT03032913 | Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC(PANC-CTC) | completed | — | 52 | University Hospital, BordeauxOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03435770 | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | unknown | N/A | 10 | Singapore General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT02978547 | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma(Metformin 001) | unknown | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03317886 | Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer | unknown | Phase 3 | 354 | Wakayama Medical UniversityOTHER | 1 | Oct 24, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2022source: clinicaltrials